Carlsbad-based True Diagnostics Inc. has entered into a collaboration with Merck KGaA in Darmstadt, Germany, a world leader in providing cardiometabolic care.
Under the agreement, True Diagnostics will collaborate with the biopharmaceutical division of Merck KGaA, which operates as EMD Serono in the United States and Canada, to help improve and increase access to thyroid care in the People's Republic of China.
The partnership allows the companies to provide medical professionals with a new and meaningful point-of-care method for rapid screening of hypothyroidism patients in minutes using only a small sample of whole-blood collected directly from the patient's fingertip.
Under the terms of the partnership, Merck KGaA will have the exclusive right to market and distribute True Diagnostics' proprietary screening assay platform and associated consumables in the thyroid care market in China. True Diagnostics received clearance in China from the China Food and Drug Administration for their TrueDX Platform and TSH (Thyroid Stimulating Hormone) test.